Building on dendritic cell subsets to improve cancer vaccines.
T cells can reject established tumors when adoptively transferred into patients, thereby demonstrating that the immune system can be harnessed for cancer therapy. However, such passive immunotherapy is unlikely to maintain memory T cells that might control tumor outgrowth on the long term. Active immunotherapy with vaccines has the potential to induce tumor-specific effector and memory T cells. Vaccines act through dendritic cells (DCs) which induce, regulate, and maintain T cell immunity. Clinical trials testing first generation DC vaccines pulsed with tumor antigens provided a proof-of-principle that therapeutic immunity can be elicited. The increased knowledge of the DC system, including the existence of distinct DC subsets is leading to new trials which aim at improved immune and clinical outcomes.
Baylor Institute for Immunology Research, Dallas, TX, USA. karolinp@baylorhealth.edu
Karolina
K
Palucka
Hideki
H
Ueno
Gerard
G
Zurawski
Joseph
J
Fay
Jacques
J
Banchereau
D000276:Adjuvants, Immunologic; D000818:Animals; D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000276:immunology*; D019496:Cancer Vaccines; D003713:Dendritic Cells / Q000276:immunology* / Q000637:transplantation; D006801:Humans; D007156:Immunologic Memory; D008213:Lymphocyte Activation; D013601:T-Lymphocytes / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines